CRVO Stock News & Analysis | Latest Updates

CervoMed to Participate in Upcoming Investor Conferences

(NASDAQ:CRVO) BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in the following investor conferences during the month of September:

September 3, 2025Investor

CRVO News

CervoMed to Participate in Upcoming Investor Conferences

D. Boral Capital Maintains Buy on CervoMed, Maintains $10 Price Target

D. Boral Capital Maintains Buy on CervoMed, Maintains $10 Price Target

Chardan Capital Maintains Buy on CervoMed, Raises Price Target to $15

CervoMed Q1 EPS $(0.56) Beats $(0.66) Estimate, Sales $1.92M Beat $1.72M Estimate

Watching CervoMed; Shares Spike Higher, Traders Circulate Newsletter Mention

CervoMed To Present New Data On Neflamapimod's Impact On DLB At 19th International Conference On Alzheimer's and Parkinson's Disease

D. Boral Capital Maintains Buy on CervoMed, Maintains $10 Price Target

CervoMed To Present At 9th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders Apr. 5

12 Health Care Stocks Moving In Friday's Intraday Session

Canaccord Genuity Maintains Buy on CervoMed, Raises Price Target to $21

Chardan Capital Maintains Buy on CervoMed, Maintains $14 Price Target

Peering Into CervoMed's Recent Short Interest

D. Boral Capital Maintains Buy on CervoMed, Maintains $10 Price Target

CervoMed FY 2024 GAAP EPS $(2.02) Misses $(1.81) Estimate, Sales $9.738M Beat $9.537M Estimate

CervoMed's Dementia Study's 16-Week Data 'Compelling Enough To Move From Sidelines' Analyst Says

Jones Trading Upgrades CervoMed to Buy, Announces $15 Price Target

This Wells Fargo Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Chardan Capital Upgrades CervoMed to Buy, Announces $14 Price Target

Roth MKM Maintains Buy on CervoMed, Raises Price Target to $15

D. Boral Capital Maintains Buy on CervoMed, Maintains $10 Price Target

CervoMed Announces Results From Extension Phase Of Phase 2b Clinical Study Of Neflamapimod

This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday

D. Boral Capital Upgrades CervoMed to Buy, Announces $10 Price Target

D. Boral Capital Initiates Coverage On CervoMed with Buy Rating, Announces Price Target of $34

Chardan Capital Maintains Buy on CervoMed, Maintains $55 Price Target

CervoMed Names William Elder As Chief Financial Officer, Effective June 1, 2024